Acucela nominates Shintaro Asako for election to its Board of Directors

– USA, WA – Acucela Inc. (TOKYO:4589), a clinical-stage biotechnology company that specializes in discovering and developing novel drug candidates to potentially treat and slow the progression of sight-threatening ophthalmic diseases, has announced that it has nominated Shintaro Asako to stand for election to the Company’s Board of Directors at the 2015 Annual Meeting of Shareholders on June 25, 2015 at Acucela’s headquarters in Seattle.…

Acucela appoints Yoshitaka Kitao, Dr. Shiro Mita, Eisaku Nakamura and Robert Takeuchi as new Board Members

– USA, WA – Acucela Inc. (TOKYO: 4589), a clinical-stage biotechnology company that specializes in discovering and developing novel drug candidates to potentially treat and slow the progression of sight-threatening ophthalmic diseases, today announced that shareholders have elected four new members to the Company’s Board of Directors at today’s special meeting of the Company’s shareholders.…